BR112021024001A2 - Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma - Google Patents

Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma

Info

Publication number
BR112021024001A2
BR112021024001A2 BR112021024001A BR112021024001A BR112021024001A2 BR 112021024001 A2 BR112021024001 A2 BR 112021024001A2 BR 112021024001 A BR112021024001 A BR 112021024001A BR 112021024001 A BR112021024001 A BR 112021024001A BR 112021024001 A2 BR112021024001 A2 BR 112021024001A2
Authority
BR
Brazil
Prior art keywords
lysozyme
methods
treatment
broad spectrum
infections
Prior art date
Application number
BR112021024001A
Other languages
English (en)
Portuguese (pt)
Inventor
Diogenes Aybar-Batista
Original Assignee
Aybar Ecotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aybar Ecotechnologies Corp filed Critical Aybar Ecotechnologies Corp
Publication of BR112021024001A2 publication Critical patent/BR112021024001A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021024001A 2019-05-28 2020-05-28 Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma BR112021024001A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853215P 2019-05-28 2019-05-28
PCT/IB2020/055083 WO2020240472A1 (en) 2019-05-28 2020-05-28 Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same

Publications (1)

Publication Number Publication Date
BR112021024001A2 true BR112021024001A2 (pt) 2022-01-25

Family

ID=73551002

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024001A BR112021024001A2 (pt) 2019-05-28 2020-05-28 Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma

Country Status (12)

Country Link
US (3) US20200376094A1 (cg-RX-API-DMAC10.html)
EP (1) EP3976093A4 (cg-RX-API-DMAC10.html)
JP (3) JP7768769B2 (cg-RX-API-DMAC10.html)
CN (1) CN114126643A (cg-RX-API-DMAC10.html)
AR (1) AR119031A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021024001A2 (cg-RX-API-DMAC10.html)
CA (1) CA3145530A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021017958A2 (cg-RX-API-DMAC10.html)
IL (1) IL288531A (cg-RX-API-DMAC10.html)
MX (1) MX2021014634A (cg-RX-API-DMAC10.html)
TW (1) TW202110474A (cg-RX-API-DMAC10.html)
WO (1) WO2020240472A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112135625B (zh) * 2020-04-27 2021-07-06 广州新创忆药物临床研究有限公司 一种预防或治疗covid-19新冠肺炎的药物及其应用
WO2023133412A2 (en) * 2022-01-05 2023-07-13 Prophase Labs, Inc. Compositions having synergistic anti-viral action and methods for treating coronavirus
CN114503981A (zh) * 2022-01-07 2022-05-17 上海膜益信息科技有限公司 一种不分层防霉液及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK501686A (da) * 1986-10-20 1988-04-21 Otto Melchior Poulsen Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det
CN1557485A (zh) * 2004-01-30 2004-12-29 大连帝恩生物工程有限公司 基因重组人溶菌酶在消除病原微生物感染炎症上的应用
ES2369670T3 (es) * 2004-04-08 2011-12-02 Dermcare-Vet Pty Ltd Composiciones antimicrobianas y métodos para su uso.
CN1583170A (zh) * 2004-06-10 2005-02-23 安米 用于抗病毒抗耐药菌的人溶菌酶药物及其制法
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
EP2207893B1 (en) * 2007-10-19 2011-12-28 Becton, Dickinson and Company Methods for the detection of beta-lactamases
WO2010036945A2 (en) * 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
UA48016U (ru) * 2010-01-25 2010-02-25 Илона Васильевна Ковач Способ профилактики кариеса зубов у детей 3-6 лет
UA68612U (ru) * 2012-02-07 2012-03-26 Дмитрий Викторович Дудар Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией
CN105611909B (zh) * 2013-03-12 2020-09-15 普莱玛疗法公司 包含螯合剂和碱的牙用组合物
ES2834950T3 (es) * 2017-02-28 2021-06-21 Prec Group Limited Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmunitaria a la infección por virus respiratorio
WO2019018368A1 (en) * 2017-07-17 2019-01-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ANTIBACTERIAL METHODS AND ASSOCIATED KITS
CN107899006A (zh) * 2017-11-28 2018-04-13 四川清舒乐科技有限公司 冲洗鼻腔的药物组合物及其制备方法

Also Published As

Publication number Publication date
US20240066105A1 (en) 2024-02-29
EP3976093A1 (en) 2022-04-06
AR119031A1 (es) 2021-11-17
CA3145530A1 (en) 2020-12-03
CO2021017958A2 (es) 2022-01-17
US20220362354A1 (en) 2022-11-17
MX2021014634A (es) 2022-07-04
IL288531A (en) 2022-01-01
JP2022534776A (ja) 2022-08-03
JP2025038034A (ja) 2025-03-18
WO2020240472A1 (en) 2020-12-03
EP3976093A4 (en) 2023-07-05
CN114126643A (zh) 2022-03-01
JP2026021451A (ja) 2026-02-10
JP7768769B2 (ja) 2025-11-12
US20200376094A1 (en) 2020-12-03
TW202110474A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
ES2828711T3 (es) Formulaciones de peróxido y métodos y aplicadores para usar las mismas
JP2020527134A5 (cg-RX-API-DMAC10.html)
CO2021017958A2 (es) Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de uso de las mismas
CN108853312B (zh) 聚桂醇外用凝胶及其制备方法
BR112021024744A2 (pt) Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington
CY1110376T1 (el) Χρηση μιας συνθεσης που περιλαμβανει φορμοτερολη και βουδεσονιδη για την προληψη απο ή τη θεραπευτικη αντιμετωπιση μιας οξειας καταστασης ασθματος
BRPI0512311A (pt) uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
BR0013222A (pt) Medicamento para aplicação tópica, uso de um xanteno halogenado, composição farmacêutica para administração tópica, e, método de tratamento
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
CO2024012872A2 (es) Tratamiento de neurofibromas plexiformes (pn) asociados a neurofibromatosis tipo 1 (nf1) en pacientes pediátricos con mirdametinib
BRPI0513168A (pt) memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia
AR052047A1 (es) Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias
EA201992759A1 (ru) Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
BR0314617A (pt) Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados
EA201170405A1 (ru) Монотерпены для лечения заболеваний дыхательных путей, в частности, бронхолегочных заболеваний
BR112023000308A2 (pt) Uso de taurolidina contra vírus
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
ES2312421T3 (es) Composicion farmaceutica en gel.
BR112022019486A2 (pt) Agente terapêutico para infecção por coronavírus
Arza Upper and lower respiratory conditions
BRPI0920492A2 (pt) uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro.
Wang et al. Tissue injury by hot fluid containing nitrogen mustard
BR112018072164A2 (pt) composição farmacêutica, método para tratamento e/ou prevenção de uma doença de pele de um paciente e/ou para alívio dos sintomas da mesma, e, uso cosmético de uma composição
BR112023021049A2 (pt) Uso de adenina na fabricação de um medicamento para tratamento de úlcera diabética

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]